These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 15955719)

  • 21. Mechanisms of corneal allograft rejection and regional immunosuppression.
    Coster DJ; Jessup CF; Williams KA
    Eye (Lond); 2009 Oct; 23(10):1894-7. PubMed ID: 19229274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of corneal allograft rejection on the long-term outcome of corneal transplantation.
    Coster DJ; Williams KA
    Am J Ophthalmol; 2005 Dec; 140(6):1112-22. PubMed ID: 16376660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Subconjunctival injection of recombinant AAV-angiostatin ameliorates alkali burn induced corneal angiogenesis.
    Cheng HC; Yeh SI; Tsao YP; Kuo PC
    Mol Vis; 2007 Dec; 13():2344-52. PubMed ID: 18199977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene therapy for corneal dystrophies and disease, where are we?
    Williams KA; Klebe S
    Curr Opin Ophthalmol; 2012 Jul; 23(4):276-9. PubMed ID: 22543480
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Viral gene therapy strategies: from basic science to clinical application.
    Young LS; Searle PF; Onion D; Mautner V
    J Pathol; 2006 Jan; 208(2):299-318. PubMed ID: 16362990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene therapy for haemophilia "A" and "B": efficacy, safety and immune consequences.
    Chuah MK; Vandendriessche T
    Bull Mem Acad R Med Belg; 2007; 162(5-6):357-61. PubMed ID: 18405006
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Non-viral and viral vectors for gene therapy.
    Boulaiz H; Marchal JA; Prados J; Melguizo C; Aránega A
    Cell Mol Biol (Noisy-le-grand); 2005 Sep; 51(1):3-22. PubMed ID: 16171561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders.
    Mandel RJ; Manfredsson FP; Foust KD; Rising A; Reimsnider S; Nash K; Burger C
    Mol Ther; 2006 Mar; 13(3):463-83. PubMed ID: 16412695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AAV-mediated gene therapy for retinal disorders: from mouse to man.
    Buch PK; Bainbridge JW; Ali RR
    Gene Ther; 2008 Jun; 15(11):849-57. PubMed ID: 18418417
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gene therapy of surfactant protein B deficiency.
    Aneja MK; Rudolph C
    Curr Opin Mol Ther; 2006 Oct; 8(5):432-8. PubMed ID: 17078385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
    Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
    Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospects and problems of gene therapy: an update.
    Górecki DC
    Expert Opin Emerg Drugs; 2001 Oct; 6(2):187-98. PubMed ID: 15989520
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hydrodynamic plasmid DNA gene therapy model in liver transplantation.
    Tsoulfas G; Takahashi Y; Liu D; Yagnik G; Wu T; Murase N; Geller DA
    J Surg Res; 2006 Oct; 135(2):242-9. PubMed ID: 16926028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A steroid-inducible promoter for the cornea.
    Parker DG; Brereton HM; Klebe S; Coster DJ; Williams KA
    Br J Ophthalmol; 2009 Sep; 93(9):1255-9. PubMed ID: 19556216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current development of adeno-associated viral vectors.
    Romano G
    Drug News Perspect; 2005 Jun; 18(5):311-6. PubMed ID: 16193103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effects of lentiviral gene therapy with bone morphogenetic protein-2-producing bone marrow cells on spinal fusion in rats.
    Miyazaki M; Sugiyama O; Tow B; Zou J; Morishita Y; Wei F; Napoli A; Sintuu C; Lieberman JR; Wang JC
    J Spinal Disord Tech; 2008 Jul; 21(5):372-9. PubMed ID: 18600149
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Gene therapy prospects in ophthalmology].
    Stopa M
    Klin Oczna; 2002; 104(3-4):289-92. PubMed ID: 12608321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene therapy for hemophilia "A" and "B": efficacy, safety and immune consequences.
    Chuah M; Vandendriessche T
    Verh K Acad Geneeskd Belg; 2007; 69(5-6):315-34. PubMed ID: 18351211
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gene therapy in transplantation in the year 2000: moving towards clinical applications?
    Guillot C; Le Mauff B; Cuturi MC; Anegon I
    Gene Ther; 2000 Jan; 7(1):14-9. PubMed ID: 10680010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.